IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-45996-4.html
   My bibliography  Save this article

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

Author

Listed:
  • Elizabeth L. Hardaker

    (Oncology R&D, AstraZeneca)

  • Emilio Sanseviero

    (Oncology R&D, AstraZeneca)

  • Ankur Karmokar

    (Oncology R&D, AstraZeneca)

  • Devon Taylor

    (Oncology R&D, AstraZeneca)

  • Marta Milo

    (Oncology R&D, AstraZeneca)

  • Chrysis Michaloglou

    (Oncology R&D, AstraZeneca)

  • Adina Hughes

    (Oncology R&D, AstraZeneca)

  • Mimi Mai

    (Oncology R&D, AstraZeneca)

  • Matthew King

    (Oncology R&D, AstraZeneca)

  • Anisha Solanki

    (Oncology R&D, AstraZeneca)

  • Lukasz Magiera

    (Oncology R&D, AstraZeneca)

  • Ricardo Miragaia

    (Oncology R&D, AstraZeneca)

  • Gozde Kar

    (Oncology R&D, AstraZeneca)

  • Nathan Standifer

    (Oncology R&D, AstraZeneca
    Tempest Therapeutics)

  • Michael Surace

    (Oncology R&D, AstraZeneca)

  • Shaan Gill

    (Oncology R&D, AstraZeneca)

  • Alison Peter

    (Oncology R&D, AstraZeneca)

  • Sara Talbot

    (Oncology R&D, AstraZeneca)

  • Sehmus Tohumeken

    (Oncology R&D, AstraZeneca)

  • Henderson Fryer

    (Oncology R&D, AstraZeneca)

  • Ali Mostafa

    (Oncology R&D, AstraZeneca)

  • Kathy Mulgrew

    (Oncology R&D, AstraZeneca)

  • Carolyn Lam

    (Oncology R&D, AstraZeneca)

  • Scott Hoffmann

    (Imaging and Data Analytics, AstraZeneca)

  • Daniel Sutton

    (Imaging and Data Analytics, AstraZeneca)

  • Larissa Carnevalli

    (Oncology R&D, AstraZeneca)

  • Fernando J. Calero-Nieto

    (Oncology R&D, AstraZeneca)

  • Gemma N. Jones

    (Oncology R&D, AstraZeneca)

  • Andrew J. Pierce

    (Oncology R&D, AstraZeneca
    Crescendo Biologics Limited)

  • Zena Wilson

    (Oncology R&D, AstraZeneca)

  • David Campbell

    (Oncology R&D, AstraZeneca)

  • Lynet Nyoni

    (Oncology R&D, AstraZeneca)

  • Carla P. Martins

    (Oncology R&D, AstraZeneca)

  • Tamara Baker

    (CPSS AST, AstraZeneca)

  • Gilberto Serrano de Almeida

    (CPSS AST, AstraZeneca)

  • Zainab Ramlaoui

    (Oncology R&D, AstraZeneca)

  • Abdel Bidar

    (CPSS, Imaging, AstraZeneca)

  • Benjamin Phillips

    (Discovery Sciences, R&D, AstraZeneca)

  • Joseph Boland

    (Oncology R&D, AstraZeneca)

  • Sonia Iyer

    (Oncology R&D, AstraZeneca)

  • J. Carl Barrett

    (Oncology R&D, AstraZeneca)

  • Arsene-Bienvenu Loembé

    (Early Clinical Development, AstraZeneca)

  • Serge Y. Fuchs

    (School of Veterinary Medicine University of Pennsylvania)

  • Umamaheswar Duvvuri

    (UPMC Department of Otolaryngology and UPMC Hillman Cancer Center)

  • Pei-Jen Lou

    (National Taiwan University Hospital)

  • Melonie A. Nance

    (University Drive C)

  • Carlos Alberto Gomez Roca

    (1 Avenue Irene Joliot-Curie, IUCT-O)

  • Elaine Cadogan

    (Oncology R&D, AstraZeneca)

  • Susan E. Critichlow

    (Oncology R&D, AstraZeneca)

  • Steven Fawell

    (Oncology R&D, AstraZeneca)

  • Mark Cobbold

    (Oncology R&D, AstraZeneca)

  • Emma Dean

    (Oncology R&D, AstraZeneca)

  • Viia Valge-Archer

    (Oncology R&D, AstraZeneca)

  • Alan Lau

    (Oncology R&D, AstraZeneca)

  • Dmitry I. Gabrilovich

    (Oncology R&D, AstraZeneca)

  • Simon T. Barry

    (Oncology R&D, AstraZeneca)

Abstract

The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8+ T-cell dependent antitumor activity, which is separate from the effects on tumor cells. Ceralasertib suppresses proliferating CD8+ T-cells on treatment which is rapidly reversed off-treatment. Ceralasertib causes up-regulation of type I interferon (IFNI) pathway in cancer patients and in tumor-bearing mice. IFNI is experimentally found to be a major mediator of antitumor activity of ceralasertib in combination with PD-L1 antibody. Improvement of T-cell function after ceralasertib treatment is linked to changes in myeloid cells in the tumor microenvironment. IFNI also promotes anti-proliferative effects of ceralasertib on tumor cells. Here, we report that broad immunomodulatory changes following intermittent ATR inhibition underpins the clinical therapeutic benefit and indicates its wider impact on antitumor immunity.

Suggested Citation

  • Elizabeth L. Hardaker & Emilio Sanseviero & Ankur Karmokar & Devon Taylor & Marta Milo & Chrysis Michaloglou & Adina Hughes & Mimi Mai & Matthew King & Anisha Solanki & Lukasz Magiera & Ricardo Miraga, 2024. "The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45996-4
    DOI: 10.1038/s41467-024-45996-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-45996-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-45996-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Filippo Veglia & Vladimir A. Tyurin & Dariush Mohammadyani & Maria Blasi & Elizabeth K. Duperret & Laxminarasimha Donthireddy & Ayumi Hashimoto & Alexandr Kapralov & Andrew Amoscato & Roberto Angelini, 2017. "Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer," Nature Communications, Nature, vol. 8(1), pages 1-16, December.
    2. Anders Lundin & Michelle J. Porritt & Himjyot Jaiswal & Frank Seeliger & Camilla Johansson & Abdel Wahad Bidar & Lukas Badertscher & Sandra Wimberger & Emma J. Davies & Elizabeth Hardaker & Carla P. M, 2020. "Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    3. Kevin Alicea-Torres & Emilio Sanseviero & Jun Gui & Jinyun Chen & Filippo Veglia & Qiujin Yu & Laxminarasimha Donthireddy & Andrew Kossenkov & Cindy Lin & Shuyu Fu & Charles Mulligan & Brian Nam & Gre, 2021. "Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    4. Hiro Sato & Atsuko Niimi & Takaaki Yasuhara & Tiara Bunga Mayang Permata & Yoshihiko Hagiwara & Mayu Isono & Endang Nuryadi & Ryota Sekine & Takahiro Oike & Sangeeta Kakoti & Yuya Yoshimoto & Kathryn , 2017. "DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells," Nature Communications, Nature, vol. 8(1), pages 1-11, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Alice Fletcher & Dean Clift & Emma Vries & Sergio Martinez Cuesta & Timothy Malcolm & Francesco Meghini & Raghothama Chaerkady & Junmin Wang & Abby Chiang & Shao Huan Samuel Weng & Jonathan Tart & Edm, 2023. "A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Bartosz Wiernicki & Sophia Maschalidi & Jonathan Pinney & Sandy Adjemian & Tom Vanden Berghe & Kodi S. Ravichandran & Peter Vandenabeele, 2022. "Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    3. I.-M. Launonen & N. Lyytikäinen & J. Casado & E. A. Anttila & A. Szabó & U.-M. Haltia & C. A. Jacobson & J. R. Lin & Z. Maliga & B. E. Howitt & K. C. Strickland & S. Santagata & K. Elias & A. D. D’And, 2022. "Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    4. Angela Criscuolo & Palina Nepachalovich & Diego Fernando Garcia-del Rio & Mike Lange & Zhixu Ni & Massimo Baroni & Gabriele Cruciani & Laura Goracci & Matthias Blüher & Maria Fedorova, 2022. "Analytical and computational workflow for in-depth analysis of oxidized complex lipids in blood plasma," Nature Communications, Nature, vol. 13(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45996-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.